MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.15

-0.3%

Nov 3 1:15 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: LJM	4/25/2008 8:31:45 PM
	of 2240

Medarex (MEDX, Trade ) shares slid 12% to $7.04. Shortly before the end of the regular session, the company said it and Bristol-Meyers Squibb Co. (BMY, Trade ) will delay filing a biologics license application for Ipilimumab, an advanced metastic melanoma treatment. The companies said the Food and Drug Administration requested additional overall survival data on the drug. They are working on a revised development timeline but the application will not be submitted this year. The companies also said they're working with the FDA to change the primary endpoint of Phase III trials of Ipilimumab to overall survival from progression-free survival, and that they're still committed to developing the treatment. <snip>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next